Phaseline

Companies › LaunXP Biomedical

LaunXP Biomedical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LXP1788 Injection–Phase 1Solid Tumor Malignancies, CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06883539LXP1788 InjectionPhase 1Solid Tumor Malignancies, CancerOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.